Global Inactivated Vaccines Market - 2025-2033

The global inactivated vaccines market reached US$ 22.60 billion in 2024 and is expected to reach US$ 34.26 billion by 2033, growing at a CAGR of 4.8% during the forecast period 2024-2032.

Vaccines are biological products that provide immunity to people against various types of infections. Vaccines consist of live-attenuated, inactivated, or remnants of pathogens, which trigger the body's immune system when administered, and aid in the production of antibodies. Inactivated vaccines are those which consist of killed pathogens, and do not provide immunity that lasts long. With inactivated vaccines, repeated doses (booster doses) are necessary to attain the required level of immunity.

The most commonly treated pathogenic infections with inactivated vaccines are polio, rabies, diphtheria, tetanus, pertussis, seasonal influenza, hepatitis A, Japanese encephalitis, etc.

Market Dynamics: Drivers & Restraints

The rising immunization programs across the globe

Vaccines are crucial in preventive healthcare, avoiding the global burden of infectious diseases. Vaccination is a routine healthcare practice worldwide to immunize newborns against deadly infections such as polio, diphtheria, tetanus, and pertussis. Global health organizations such as the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), and others are actively involved in vaccination programs aiming to eradicate these infections. These programs are anticipated to improve access to inactivated vaccines and create a higher demand for them propelling their market growth.

For instance, global health organizations have recently extended the Polio Eradication Strategy 2022-2026 to the end of 2029 to eradicate wild poliovirus type 1 (WPV1) by the end of 2027 and eliminate circulating type 2 variant poliovirus (cVDPV2/ vaccine-derived poliovirus) by the end of 2029. This program was supported by governments across the world and has provided a fund of nearly US$ 2.4 billion for the extended program. The major outcome of this program extension is an improved vaccination rate benefiting the manufacturers to improve their sales value and volume, also driving market growth.

Supply chain discrepancies may restrain the market growth.

Supply chain discrepancies can tremendously impact the market of inactivated vaccines, by reducing vaccine coverage, impacting the global immunization programs, and deflecting the overall market. These supply chain discrepancies are caused by limited production outpaced by global demand, limited manufacturers, sudden outbreaks, etc. For instance, in 2024, a cholera outbreak was reported by the World Health Organization, with 307,433 cases and 2,326 deaths from 26 countries. There is a higher demand for Dukoral, an inactivated cholera vaccine, and this vaccine shortage was reported in various countries including the United Kingdom. This limited supply of vaccines can hinder the opportunity to capitalize on the larger demand.

Segment Analysis

The global inactivated vaccines market is segmented based on pathogen, vaccine type, and region.

Influenza vaccine in the vaccine type segment is dominating the market.

Influenza vaccines also known as flu shots are the ones that protect the recipient against influenza viruses which cause respiratory illnesses. Vaccination is currently the best preventive measure to fight influenza viruses. As per the World Health Organization (WHO), between 3 to 5 million severe influenza cases are reported each year, and 290k to 650k respiratory deaths. The WHO also states that the influenza virus is constantly evolving which requires frequent reformulation of influenza vaccines, and annual immunization. The inactivated influenza vaccines are the most widely used and are categorized as trivalent (3 strains; TIV) and quadrivalent (4 strains; QIV). These vaccines possess excellent safety profiles with minimal side effects and can be prescribed to anyone above 6 months of age, including special populations such as pregnant women.

The market for influenza vaccines is high among all the inactivated vaccines, majorly due to their higher demand during flu season each year, and frequency of administration. The Global Vaccine Report by the WHO states that Influenza vaccines are the ones with high sales value and volume as they are sold in high-income countries where the disease burden is also high.

Geographical Analysis

North America dominated the inactivated vaccines market.

North America region is well known for its advanced healthcare system, public health policies, and immunization programs. The U.S., which is the global leader in the healthcare industry, houses vaccine manufacturers who sell advanced vaccines, meeting the demands of the country. As the U.S. is a high-income country there is a clear disparity in the prices they pay as compared to other nations of the world. Manufacturers tend to generate most of their revenue from the region due to higher vaccine costs, which is a major contributor to the region's dominance.

For instance, influenza vaccine is the dominating one in the inactivated vaccines market. Sanofi is a global leader in the manufacturing and supply of inactivated influenza vaccines. In 2023, the company reported a sale of 2,699 Euro million (2,886 USD million) for influenza vaccines of which ~52% of the sales are from the U.S. market.

The burden of infectious diseases is also high in the region, creating a higher demand for inactivated vaccines. For instance, as per the Centers for Disease Control and Prevention (CDC), in the U.S. nearly 40 million respiratory illnesses, 470k hospitalizations, and 28k deaths resulted from influenza infections in 2023-2024.

All these factors reflect why the North America region, especially the U.S. dominates the global inactivated vaccines market.

Competitive Landscape

The major global players in the inactivated vaccines market are Serum Institute of India Pvt. Ltd., GSK plc., Sanofi., Biological E Limited., Bharat Biotech., Bio Farma, Merck & Co., Inc., Valneva SE., Pfizer Inc., and KM Biologics among others.

Key Developments

• In June 2024, Sanofi announced a partnership with Biovac to start local manufacturing of inactivated polio vaccines (IPV) in Africa. This partnership enables polio vaccine supply to more than 40 African countries in the future and also supports the Africa CDC goal to have 60% of local vaccine production goal by 2040.
• In April 2024, the World Health Organization (WHO) provided prequalification for new oral inactivated cholera vaccine Euvichol-S. This prequalification adds the third product to the list of oral inactivated cholera vaccines produced by EuBiologicals Co.Ltd.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global melanoma therapeutics market report would provide approximately 54 tables, 46 figures, and 195 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.